Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Por Sims, Robert B.
Publicado em 2011

The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer

Por Mouraviev, Vladimir, Mariados, Neil, Albala, David, Concepcion, Raoul S, Shore, Neal D, Sims, Robert B, Emberton, Mark, Pieczonka, Christopher M
Publicado em 2014

A Transient Increase in Eosinophils is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T

Por McNeel, Douglas G., Gardner, Thomas A., Higano, Celestia S., Kantoff, Philip W., Small, Eric J., Wener, Mark H., Sims, Robert B., DeVries, Todd, Sheikh, Nadeem A., Dreicer, Robert
Publicado em 2014

A Phase 1 Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu

Por Peethambaram, Prema P., Melisko, Michelle E., Rinn, Kristine J., Alberts, Steven R., Provost, Nicole M., Jones, Lori A., Sims, Robert B., Lin, Lisa R.C., Frohlich, Mark W., Park, John W.
Publicado em 2009

Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer

Por Fong, Lawrence, Carroll, Peter, Weinberg, Vivian, Chan, Stephen, Lewis, Jera, Corman, John, Amling, Christopher L., Stephenson, Robert A., Simko, Jeffrey, Sheikh, Nadeem A., Sims, Robert B., Frohlich, Mark W., Small, Eric J.
Publicado no J Natl Cancer Inst (2014)